[Show abstract][Hide abstract] ABSTRACT: Background: The National Lung Screening Trial demonstrated that screening for lung cancer improved overall survival (OS) and reduced lung cancer mortality in the 55- to 74-year-old age group by increasing the proportion of cancers detected at an early stage. Because of the increasing life expectancy of the American population, we investigated whether screening for lung cancer might benefit men and women aged 75-84 years. Materials/Methods: Rates of non-small cell lung cancer (NSCLC) from 2000 to 2009 were calculated in both younger and older age groups using the surveillance epidemiology and end reporting database. OS and lung cancer-specific survival (LCSS) in patients with Stage I NSCLC diagnosed from 2004 to 2009 were analyzed to determine the effects of age and treatment. Results: The per capita incidence of NSCLC decreased in the 55-74 cohort, but increased in the 75-84 cohort over the study period. Crude lung cancer death rates in the two age groups who had no specific treatment were 39.5 and 44.9%, respectively. These rates fell in both age groups when increasingly aggressive treatment was used. Rates of OS and LCSS improved significantly with increasingly aggressive treatment in the 75-84 age group. The survival benefits of increasingly aggressive treatment in 75- to 84-year-old females did not differ from their counterparts in the younger cohort. Conclusion: Screening for lung cancer might be of benefit to individuals at increased risk of lung cancer in the 75-84 age group. The survival benefits of aggressive therapy are similar in females between 55-74 and 75-84 years old.
[Show abstract][Hide abstract] ABSTRACT: OBJECTIVE: An increasing proportion of patients with stage I non-small cell lung cancer (NSCLC) is undergoing sublobar resection (L-). However, there is little information about the risks and correlates of local recurrence (LR) after such surgery, especially compared with patients undergoing lobectomy (L+). METHODS: Ninety-three and 318 consecutive patients with stage I NSCLC underwent L- and L+, respectively, from 2000 to 2006. Median follow-up was 34 months. RESULTS: In the L- group, the LR rates at 2, 3, and 5 years were 13%, 24%, and 40%, respectively. The risk of LR was significantly associated with tumor grade, tumor size, and T stage. The crude risk of LR was 33.8% (21 of 62) for patients whose tumors were grade ≥ 2. In the L+ group, the LR rates at 2, 3, and 5 years were 14%, 19%, and 24%, respectively. The risk of LR significantly increased with increasing tumor size, length of hospital stay, and the presence of diabetes. The L- group experienced a significant increase in failure in the bronchial stump/staple line compared with the L+ group (10% vs 3%; P = .04) and nonsignificant trends toward increased ipsilateral hilar and subcarinal failure rates. CONCLUSIONS: Patients with stage I NSCLC who undergo L- have an increased risk of LR compared with patients undergoing L+, particularly when they have tumors grade ≥ 2 or tumor size > 2 cm. If L- is considered, additional local therapy should be considered to reduce this risk of LR, especially with tumors grade ≥ 2 or size > 2 cm.
[Show abstract][Hide abstract] ABSTRACT: We review the evidence for optimal surgical management and adjuvant therapy for patients with stages I and II non-small cell lung cancer (NSCLC) along with factors associated with increased risks of recurrence. Based on the current evidence, we recommend optimal use of mediastinal lymph node dissection, adjuvant chemotherapy, and post-operative radiation therapy, and make suggestions for areas to explore in future prospective randomized clinical trials.
International journal of radiation oncology, biology, physics 05/2012; · 4.59 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: We recently demonstrated that diabetes mellitus was an independent risk factor for local recurrence (LR) for patients undergoing resection of non-small cell lung cancer (NSCLC). This investigation was performed to confirm or refute this finding in a different patient cohort.
Patients were eligible if they did not have a second primary cancer within 5 years of the original diagnosis, had at least 3-month follow-up, and did not receive radiotherapy. There were 373 and 168 patients in the original (P1) and confirmatory (P2) cohorts, respectively, with 66 and 30 patients with diabetes.
The median follow-up was 33 months (range, 3-98 months). Diabetes was an independent risk factor for LR in a Cox model in both the P2 (p=0.05, hazard ratio [HR] 2.15) and P1 (p=0.008, HR 1.90) cohorts, separately from BMI, glucose control, and the presence of the metabolic syndrome. The rates of LR in the patients with diabetes after combining the cohorts at 2, 3, and 5 years were 23%, 33%, and 56%, respectively; these rates were 15%, 19%, and 26% in non-diabetics. In multivariate Cox regression and competing risk analysis of the combined cohorts, the HRs for LR in patients with diabetes exceeded those of more established risk factors for LR including a 1-cm increase in tumor size and lymphovascular invasion.
Diabetes was confirmed to be an independent predictor of the risk of LR following resection of NSCLC.
Lung cancer (Amsterdam, Netherlands) 08/2011; 75(3):381-90. · 3.14 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: PURPOSE
To assess failure pattern (local vs distal) and patient, treatment and histologic factors associated with local, distal or risk of any failure (local or distal) in pts with completely-resected Stage I NSCLC.
METHOD AND MATERIALS
The study included 282 consecutive pts operated on from 2000-05 who did not receive adjuvant/neo-adjuvant radiotherapy, had at least 3 months of follow-up, and did not have a history of other cancers within 5 years of NSCLC. 52, 225, and 11 pts were treated by a wedge resection/segmentectomy, lobectomy/bi-lobectomy, and pneumonectomy, respectively. 17 pts received adjuvant chemotherapy. Multivariable logistic regression analysis was performed to analyze factors associated with failure. Failure rates were calculated according to the Kaplan-Meier method.
Median follow-up was 33 months. Local, distal and any failure rate were 13.3, 10.8, and 20.0% at 2 years; 18.5, 12.7, and 26.4% at 3 years; 28.9, 18.0, and 38.2% at 5 years. Multivariable analysis was performed and demonstrated that local failure was associated with presence of an asymptomatic nodule (p=0.0359, OR=0.49) and presence of diabetes at diagnosis (p= 0.0018, OR=3.47); distal failure was associated with cough (p =0.0436, OR= 2.19); and any failure was associated with cough (p= 0.0411, OR=1.90), diabetes (p = 0.0021, OR=3.32), tumor size (p=0.0132, OR=1.19), and length of hospital stay ( p= 0.0377, OR=1.06). The most common sites of local recurrence were the ipsilateral lung (55.2%), the ipsilateral mediastinum (22.4%), and the bronchial stump (25.9%).
Local recurrence is the predominant failure pattern after the surgical resection of NSCLC. The presence of diabetes at diagnosis is the most significant factor associated with local recurrence.
Radiological Society of North America 2008 Scientific Assembly and Annual Meeting; 12/2008